Company names starting with "A"

Patents whose numbers are in italics have been extended under 35 USC 156. Unless otherwise noted, all expiration dates include applicable Sec. 156 and pediatric (PED) extensions.
Products tagged as [GENERIC] have had a generic equivalent approved for at least one strength of the product.


ABBOTT
CALCIJEX (INJECTABLE) CALCITRIOL [GENERIC AP]
Drug Classes: VITAMINS/MINERALS; CALCIUM METABOLISM
NDA Applicant: ABBOTT      NDA No.:
018874  Prod. No.: 001 RX (0.001MG/ML); 002 RX (0.002MG/ML)
PatentsExpirationPatented Use
Pat. No. 6051567 Low oxygen content compositions of 1.alpha., 25-dihydroxycholecalciferol
Claim Types: Formulation
FEB 02,2020 *PED 
Pat. No. 6265392 Low oxygen content compositions of 1.alpha., 25-dihydroxycholeclciferol
Claim Types: Formulation
FEB 02,2020 *PED 
Pat. No. 6274169 Low oxygen content compostions of 1.alpha., 25-dihydroxycholecalciferol
Claim Types: Process; Product-by-process
FEB 02,2020 *PED 
ExclusivityExpirationExclusivity Description
Exclusivity Code: M - MiscellaneousMay 16,2005 PEDM-14: Additional clinical trial information added to pediatric use subsection

ABBOTT
DEPACON (INJECTABLE) VALPROATE SODIUM [GENERIC AP]
Drug Classes: ANTICONVULSANTS
NDA Applicant: ABBOTT      NDA No.:
020593  Prod. No.: 001 RX (EQ 100MG BASE/ML)
ExclusivityExpirationExclusivity Description
Exclusivity Code: D - New Dosing ScheduleJAN 24,2005D-72: Information regarding increased rate of infusion for DEPACON

ABBOTT
DEPAKOTE (TABLET, DELAYED RELEASE) DIVALPROEX SODIUM
Drug Classes: ANTICONVULSANTS
NDA Applicant: ABBOTT      NDA No.:
018723  Prod. No.: 001 RX (EQ 250MG VALPROIC ACID); 002 RX (EQ 500MG VALPROIC ACID); 003 RX (EQ 125MG VALPROIC ACID)
PatentsExpirationPatented Use
Pat. No. 4988731 Sodium hydrogen divalproate oligomer
Claim Types: Composition
JAN 29,2008 
Pat. No. 5212326 Sodium hydrogen divalproate oligomer
Claim Types: Composition
JAN 29,2008 

ABBOTT
DEPAKOTE (CAPSULE, DELAYED REL PELLETS) DIVALPROEX SODIUM
Drug Classes: ANTICONVULSANTS
NDA Applicant: ABBOTT      NDA No.:
019680  Prod. No.: 001 RX (EQ 125MG VALPROIC ACID)
PatentsExpirationPatented Use
Pat. No. 4988731 Sodium hydrogen divalproate oligomer
Claim Types: Composition
JAN 29,2008 
Pat. No. 5212326 Sodium hydrogen divalproate oligomer
Claim Types: Composition
JAN 29,2008 

ABBOTT
DEPAKOTE CP (TABLET, DELAYED RELEASE) DIVALPROEX SODIUM
NDA Applicant: ABBOTT      NDA No.:
019794  Prod. No.: 001 DISC (EQ 250MG BASE); 002 DISC (EQ 500MG BASE)
PatentsExpirationPatented Use
Pat. No. 4988731 Sodium hydrogen divalproate oligomer
Claim Types: Composition
JAN 29,2008 
Pat. No. 5212326 Sodium hydrogen divalproate oligomer
Claim Types: Composition
JAN 29,2008 

ABBOTT
DEPAKOTE ER (TABLET, EXTENDED RELEASE) DIVALPROEX SODIUM
NDA Applicant: ABBOTT      NDA No.:
021168  Prod. No.: 001 RX (EQ 500MG VALPROIC ACID)
PatentsExpirationPatented Use
Pat. No. 4913906 Novel controlled release dosage form of valproic acid
Claim Types: Formulation; Process
APR 03,2007 
Pat. No. 4988731 Sodium hydrogen divalproate oligomer
Claim Types: Composition
JAN 29,2008 
Pat. No. 5212326 DS* DP* Sodium hydrogen divalproate oligomer
Claim Types: Composition
JAN 29,2008 
Pat. No. 6419953 Controlled release formulation of divalproex sodium
Claim Types: Formulation; Process; Method of use
DEC 18,2018 
Pat. No. 6511678 Controlled release formulation of divalproex sodium
Claim Types: Formulation; Method of use
DEC 18,2018 
Pat. No. 6528090 DP* Controlled release formulation of divalproex sodium
Claim Types: Formulation
DEC 18,2018 
Pat. No. 6528091 Controlled release formulation of divalproex sodium
Claim Types: Method of use
DEC 18,2018U-106: Treatment of epilepsy
Pat. No. 6713086 DP* Controlled release formulation of divalproex sodium
Claim Types: Formulation; Method of use
DEC 18,2018U-579: Treatment of epilepsy and/or migraine.
Pat. No. 6720004 DP* Controlled release formulation of divalproex sodium
Claim Types: Formulation
DEC 18,2018 

ABBOTT
DEPAKOTE ER (TABLET, EXTENDED RELEASE) DIVALPROEX SODIUM
NDA Applicant: ABBOTT      NDA No.:
021168  Prod. No.: 002 RX (EQ 250MG VALPROIC ACID)
PatentsExpirationPatented Use
Pat. No. 4913906 Novel controlled release dosage form of valproic acid
Claim Types: Formulation; Process
APR 03,2007 
Pat. No. 4988731 Sodium hydrogen divalproate oligomer
Claim Types: Composition
JAN 29,2008 
Pat. No. 5212326 DS* DP* Sodium hydrogen divalproate oligomer
Claim Types: Composition
JAN 29,2008 
Pat. No. 6511678 Controlled release formulation of divalproex sodium
Claim Types: Formulation; Method of use
DEC 18,2018 
Pat. No. 6528090 DP* Controlled release formulation of divalproex sodium
Claim Types: Formulation
DEC 18,2018 
Pat. No. 6713086 DP* Controlled release formulation of divalproex sodium
Claim Types: Formulation; Method of use
DEC 18,2018U-579: Treatment of epilepsy and/or migraine.
Pat. No. 6720004 DP* Controlled release formulation of divalproex sodium
Claim Types: Formulation
DEC 18,2018 

ABBOTT
HYTRIN (TABLET) TERAZOSIN HYDROCHLORIDE [GENERIC AB]
Drug Classes: ANTIHYPERTENSIVES; DIURETICS
NDA Applicant: ABBOTT      NDA No.:
019057  Prod. No.: 001 RX (EQ 1MG BASE); 002 RX (EQ 2MG BASE); 003 RX (EQ 5MG BASE); 004 RX (EQ 10MG BASE)
PatentsExpirationPatented Use
Pat. No. 5212176 R(+)-terazosin
Claim Types: Compound; Composition; Method of use
JUN 29,2010 
Pat. No. 5294615 Terazosin polymorph and pharmaceutical composition
Claim Types: New polymorph, salt or hydrate; Composition; Method of use
APR 29,2013U-165: Treatment of symptomatic benign prostatic hyperplasia
Pat. No. 5294615 Terazosin polymorph and pharmaceutical composition
Claim Types: New polymorph, salt or hydrate; Composition; Method of use
APR 29,2013U-3: Treatment of hypertension
Pat. No. 5412095 Terazosin monohydrochloride and processes and intermediate for its production
Claim Types: New polymorph, salt or hydrate
APR 29,2013 

ABBOTT
HYTRIN (CAPSULE) TERAZOSIN HYDROCHLORIDE [GENERIC AB]
Drug Classes: ANTIHYPERTENSIVES; ALPHA AGONISTS/ALPHA BLOCKERS
NDA Applicant: ABBOTT      NDA No.:
020347  Prod. No.: 001 RX (EQ 1MG BASE); 002 RX (EQ 2MG BASE); 003 RX (EQ 5MG BASE); 004 RX (EQ 10MG BASE)
PatentsExpirationPatented Use
Pat. No. 5212176 R(+)-terazosin
Claim Types: Compound; Composition; Method of use
JUN 29,2010 
Pat. No. 5294615 Terazosin polymorph and pharmaceutical composition
Claim Types: New polymorph, salt or hydrate; Composition; Method of use
APR 29,2013U-165: Treatment of symptomatic benign prostatic hyperplasia
Pat. No. 5294615 Terazosin polymorph and pharmaceutical composition
Claim Types: New polymorph, salt or hydrate; Composition; Method of use
APR 29,2013U-3: Treatment of hypertension
Pat. No. 5412095 Terazosin monohydrochloride and processes and intermediate for its production
Claim Types: New polymorph, salt or hydrate
APR 29,2013 

ABBOTT
KALETRA (CAPSULE) LOPINAVIR; RITONAVIR
Drug Classes: ANTIVIRALS
NDA Applicant: ABBOTT      NDA No.:
021226  Prod. No.: 001 RX (133.3MG;33.3MG)
PatentsExpirationPatented Use
Pat. No. 5541206 Retroviral protease inhibiting compounds
Claim Types: Compound; Composition; Method of use
JUL 30,2013U-348: Method of use for inhibiting HIV infection
Pat. No. 5635523 Retroviral protease inhibiting compounds
Claim Types: Method of use
JUN 30,2014U-352: Inhibiting HIV infection by administering ritonavir in combination with a reverse transcriptase inhibitor
Pat. No. 5648497 Retroviral protease inhibiting compounds
Claim Types: Compound
JUL 15,2014 
Pat. No. 5674882 Retroviral protease inhibiting compounds
Claim Types: Method of use
OCT 07,2014U-344: Method for inhibiting HIV infection by administering ritonavir in combination with another HIV protease inhibitor
Pat. No. 5846987 Retroviral protease inhibiting compounds
Claim Types: Composition; Use of compound to prepare a composition
DEC 29,2012U-350: Preparation of a pharmaceutical composition for concomitant admin with a reverse transcriptase inhibitor
Pat. No. 5886036 Retroviral protease inhibiting compounds
Claim Types: Composition
DEC 29,2012U-345: Ritonavir and another HIV protease inhibitor for concomitant administration for the treatment of an HIV infection
Pat. No. 5914332 Retroviral protease inhibiting compounds
Claim Types: Compound; Composition; Method of use
DEC 13,2015U-351: Inhibiting protease with lopinavir and inhibiting an HIV infection with lopinavir
Pat. No. 6037157 Method for improving pharmacokinetics
Claim Types: Method of use
JUN 26,2016U-346: Method for inhibiting cytochrome p450 monooxygenase with ritonavir and a method for improving the pharmcokinetics of a drug that is metabolized by cytochrome P450 monooxygenase by admin the drug and RITONAVIR
Pat. No. 6232333 Pharmaceutical composition
Claim Types: Formulation
NOV 07,2017 
Pat. No. 6284767 Retroviral protease inhibiting compounds
Claim Types: Composition; Method of use
FEB 14,2016U-401: Use of lopinavir in combination with reverse transcriptase inhibitors for treating HIV infection and in combo with other HIV protease inhibitors
Pat. No. 6458818 Pharmaceutical composition
Claim Types: Formulation
NOV 07,2017 
Pat. No. 6521651 Pharmaceutical composition
Claim Types: Formulation
NOV 01,2017 
Pat. No. 6703403 Method for improving pharmacokinetics
Claim Types: Method of improving a treatment
JUN 26,2016U-257: Treatment of HIV infection
ExclusivityExpirationExclusivity Description
Exclusivity Code: D - New Dosing ScheduleAPR 29,2008D-99: Once daily administration for the treatment of HIV infection in therapy naive adult patients

ABBOTT
KALETRA (SOLUTION) LOPINAVIR; RITONAVIR
NDA Applicant: ABBOTT      NDA No.:
021251  Prod. No.: 001 RX (80MG/ML;20MG/ML)
PatentsExpirationPatented Use
Pat. No. 5541206 Retroviral protease inhibiting compounds
Claim Types: Compound; Composition; Method of use
JUL 30,2013U-348: Method of use for inhibiting HIV infection
Pat. No. 5635523 Retroviral protease inhibiting compounds
Claim Types: Method of use
JUN 03,2014U-352: Inhibiting HIV infection by administering ritonavir in combination with a reverse transcriptase inhibitor
Pat. No. 5648497 Retroviral protease inhibiting compounds
Claim Types: Compound
JUL 15,2014 
Pat. No. 5674882 Retroviral protease inhibiting compounds
Claim Types: Method of use
OCT 07,2014U-344: Method for inhibiting HIV infection by administering ritonavir in combination with another HIV protease inhibitor
Pat. No. 5846987 Retroviral protease inhibiting compounds
Claim Types: Composition; Use of compound to prepare a composition
DEC 29,2012U-350: Preparation of a pharmaceutical composition for concomitant admin with a reverse transcriptase inhibitor
Pat. No. 5886036 Retroviral protease inhibiting compounds
Claim Types: Composition
DEC 29,2012U-345: Ritonavir and another HIV protease inhibitor for concomitant administration for the treatment of an HIV infection
Pat. No. 5914332 Retroviral protease inhibiting compounds
Claim Types: Compound; Composition; Method of use
DEC 13,2005U-351: Inhibiting protease with lopinavir and inhibiting an HIV infection with lopinavir
Pat. No. 6037157 Method for improving pharmacokinetics
Claim Types: Method of use
JUN 26,2016U-346: Method for inhibiting cytochrome p450 monooxygenase with ritonavir and a method for improving the pharmcokinetics of a drug that is metabolized by cytochrome P450 monooxygenase by admin the drug and RITONAVIR
Pat. No. 6284767 Retroviral protease inhibiting compounds
Claim Types: Composition; Method of use
FEB 14,2016U-401: Use of lopinavir in combination with reverse transcriptase inhibitors for treating HIV infection and in combo with other HIV protease inhibitors
Pat. No. 6703403 Method for improving pharmacokinetics
Claim Types: Method of improving a treatment
JUN 26,2016U-257: Treatment of HIV infection
ExclusivityExpirationExclusivity Description
Exclusivity Code: D - New Dosing ScheduleAPR 29,2008D-99: Once daily administration for the treatment of HIV infection in therapy naive adult patients

ABBOTT
MAVIK (TABLET) TRANDOLAPRIL
Drug Classes: ACE INHIBITORS; ANTIHYPERTENSIVES
NDA Applicant: ABBOTT      NDA No.:
020528  Prod. No.: 001 RX (1MG); 002 RX (2MG); 003 RX (4MG)
PatentsExpirationPatented Use
Pat. No. 4933361 Derivatives of bicyclic aminoacids agents containing these compounds and their use
Claim Types: Compound; Composition; Method of use
JUN 12,2007 
Pat. No. 5744496 Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors
Claim Types: Method of use
APR 28,2015U-229: Cardiac insufficiency (congestive heart failure)

ABBOTT
MERIDIA (CAPSULE) SIBUTRAMINE HYDROCHLORIDE
Drug Classes: ANOREXIANTS/CNS STIMULANTS; CNS, MISCELLANEOUS
NDA Applicant: ABBOTT      NDA No.:
020632  Prod. No.: 001 RX (5MG); 002 RX (10MG); 003 RX (15MG)
PatentsExpirationPatented Use
Pat. No. 4746680 [Extended 5 years]
Therapeutic agents
Claim Types: Compound; Composition; Method of use
DEC 11,2007 *PED 
Pat. No. 4929629 Therapeutic compound
Claim Types: Compound; Composition; Method of use
NOV 29,2007 *PED 
Pat. No. 5436272 Treatment of obesity
Claim Types: Method of use
JAN 25,2013 *PEDU-439: Treatment of obesity

ABBOTT
MIVACRON; MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE) MIVACURIUM CHLORIDE
NDA Applicant: ABBOTT      NDA No.:
020098  Prod. No.: 001 RX (EQ 2MG BASE/ML) NDA No.: 020098  Prod. No.: 002 DISC (EQ 0.5MG BASE/ML)
PatentsExpirationPatented Use
Pat. No. 4761418 [Extended 173 days (0.5 years)]
Novel compounds
Claim Types: Compound; Composition; Method of use
JAN 22,2006 

ABBOTT
NIMBEX; NIMBEX PRESERVATIVE FREE (INJECTABLE) CISATRACURIUM BESYLATE
Drug Classes: ANESTHESIA, ADJUNCTS TO/ANALEPTICS
NDA Applicant: ABBOTT      NDA No.:
020551  Prod. No.: 001 RX (EQ 2MG BASE/ML); 002 RX (EQ 10MG BASE/ML); 003 RX (EQ 2MG BASE/ML)
PatentsExpirationPatented Use
Pat. No. 5453510 Neuromuscular blocking agents
Claim Types: Formulation; Method of use
SEP 26,2012U-127: Method of producing neuromuscular blockade

ABBOTT
NORVIR (SOLUTION) RITONAVIR
Drug Classes: ANTIVIRALS
NDA Applicant: ABBOTT      NDA No.:
020659  Prod. No.: 001 RX (80MG/ML)
PatentsExpirationPatented Use
Pat. No. 5484801 Pharmaceutical composition for inhibiting HIV protease
Claim Types: Formulation
JAN 28,2014 
Pat. No. 5541206 Retroviral protease inhibiting compounds
Claim Types: Compound; Composition; Method of use
JUL 30,2013U-140: Use of NORVIR to inhibit HIV protease or to inhibit an HIV infection
Pat. No. 5635523 Retroviral protease inhibiting compounds
Claim Types: Method of use
JUN 03,2014U-190: Use of ritonavir in combination with any reverse transcriptase inhibitor
Pat. No. 5648497 Retroviral protease inhibiting compounds
Claim Types: Compound
JUL 15,2014 
Pat. No. 5674882 Retroviral protease inhibiting compounds
Claim Types: Method of use
OCT 07,2014 
Pat. No. 5846987 Retroviral protease inhibiting compounds
Claim Types: Composition; Use of compound to prepare a composition
DEC 29,2012U-190: Use of ritonavir in combination with any reverse transcriptase inhibitor
Pat. No. 5886036 Retroviral protease inhibiting compounds
Claim Types: Composition
DEC 29,2012 
Pat. No. 6037157 Method for improving pharmacokinetics
Claim Types: Method of use
JUN 26,2016 
Pat. No. 6703403 Method for improving pharmacokinetics
Claim Types: Method of improving a treatment
JUN 26,2016U-564: Treatment of HIV in concomitant therapy

ABBOTT
NORVIR (CAPSULE) RITONAVIR
Drug Classes: ANTIVIRALS
NDA Applicant: ABBOTT      NDA No.:
020680  Prod. No.: 001 DISC (100MG)
PatentsExpirationPatented Use
Pat. No. 5541206 Retroviral protease inhibiting compounds
Claim Types: Compound; Composition; Method of use
JUL 30,2013U-140: Use of NORVIR to inhibit HIV protease or to inhibit an HIV infection
Pat. No. 5635523 Retroviral protease inhibiting compounds
Claim Types: Method of use
JUN 03,2014U-190: Use of ritonavir in combination with any reverse transcriptase inhibitor
Pat. No. 5648497 Retroviral protease inhibiting compounds
Claim Types: Compound
JUL 15,2014 
Pat. No. 5846987 Retroviral protease inhibiting compounds
Claim Types: Composition; Use of compound to prepare a composition
DEC 29,2012U-190: Use of ritonavir in combination with any reverse transcriptase inhibitor
Pat. No. 5948436 Pharmaceutical composition
Claim Types: Formulation
SEP 13,2013 

ABBOTT
NORVIR (CAPSULE) RITONAVIR
Drug Classes: ANTIVIRALS
NDA Applicant: ABBOTT      NDA No.:
020945  Prod. No.: 001 RX (100MG)
PatentsExpirationPatented Use
Pat. No. 5541206 Retroviral protease inhibiting compounds
Claim Types: Compound; Composition; Method of use
JUL 30,2013U-348: Method of use for inhibiting HIV infection
Pat. No. 5635523 Retroviral protease inhibiting compounds
Claim Types: Method of use
JUN 03,2014U-347: Method of use in combination with reverse transcriptase inhibitors
Pat. No. 5648497 Retroviral protease inhibiting compounds
Claim Types: Compound
JUL 15,2014 
Pat. No. 5846987 Retroviral protease inhibiting compounds
Claim Types: Composition; Use of compound to prepare a composition
DEC 29,2012U-347: Method of use in combination with reverse transcriptase inhibitors
Pat. No. 6232333 Pharmaceutical composition
Claim Types: Formulation
NOV 07,2017 
Pat. No. 6703403 Method for improving pharmacokinetics
Claim Types: Method of improving a treatment
JUN 26,2016U-564: Treatment of HIV in concomitant therapy

ABBOTT
NUROMAX (INJECTABLE) DOXACURIUM CHLORIDE
NDA Applicant: ABBOTT      NDA No.:
019946  Prod. No.: 001 DISC (EQ 1MG BASE/ML)
PatentsExpirationPatented Use
Pat. No. 4701460 [Extended 137 days (0.4 years)]
Long duration neuromuscular blocking agents
Claim Types: Compound; Method of use; Composition
MAR 06,2005 

ABBOTT
TARKA (TABLET, EXTENDED RELEASE) TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE
Drug Classes: ANTIHYPERTENSIVES
NDA Applicant: ABBOTT      NDA No.:
020591  Prod. No.: 001 RX (2MG;180MG); 002 RX (4MG;240MG); 003 RX (1MG;240MG); 004 RX (2MG;240MG)
PatentsExpirationPatented Use
Pat. No. 4933361 Derivatives of bicyclic aminoacids agents containing these compounds and their use
Claim Types: Compound; Composition; Method of use
JUN 12,2007 
Pat. No. 5721244 Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs
Claim Types: Composition; Method of use
FEB 24,2015 

ABBOTT
TRICOR (TABLET) FENOFIBRATE [GENERIC AB]
Drug Classes: HYPERLIPIDEMIA
NDA Applicant: ABBOTT      NDA No.:
021203  Prod. No.: 001 RX (54MG); 003 RX (160MG)
PatentsExpirationPatented Use
Pat. No. 4895726 Novel dosage form of fenofibrate
Claim Types: Formulation; Method of use; Process
JAN 19,2009 
Pat. No. 6074670 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Claim Types: Formulation
JAN 09,2018 
Pat. No. 6277405 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Claim Types: Formulation
JAN 09,2018 
Pat. No. 6589552 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Claim Types: Formulation
JAN 09,2018 
Pat. No. 6652881 DP* Fenofibrate pharmaceutical composition having high bioavailability
Claim Types: Formulation
JAN 09,2018 

ABBOTT
TRICOR (TABLET) FENOFIBRATE
NDA Applicant: ABBOTT      NDA No.:
021656  Prod. No.: 001 RX (48MG); 002 RX (145MG)
PatentsExpirationPatented Use
Pat. No. 5145684 DP* Surface modified drug nanoparticles
Claim Types: Composition; Method of use; Process
JAN 25,2011U-615: Adjunctive therapy to diet in adults to reduce LDL-c, total-c, triglycerides and APO B, and increase HDL-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types IIa, IIb) and to treat hypertriglyceridemia (types IV, V)
Pat. No. 6277405 DS* Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Claim Types: Formulation
JAN 09,2018 
Pat. No. 6375986 DP* Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
Claim Types: Formulation; Process; Method of use
SEP 21,2020U-615: Adjunctive therapy to diet in adults to reduce LDL-c, total-c, triglycerides and APO B, and increase HDL-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types IIa, IIb) and to treat hypertriglyceridemia (types IV, V)
Pat. No. 6652881 DS* Fenofibrate pharmaceutical composition having high bioavailability
Claim Types: Formulation
JAN 09,2018 

ABBOTT
TRICOR (MICRONIZED) (CAPSULE) FENOFIBRATE [Has competitive generic]
Drug Classes: HYPERLIPIDEMIA
NDA Applicant: ABBOTT      NDA No.:
019304  Prod. No.: 002 DISC (67MG); 003 DISC (134MG); 004 DISC (200MG)
PatentsExpirationPatented Use
Pat. No. 4895726 Novel dosage form of fenofibrate
Claim Types: Formulation; Method of use; Process
JAN 19,2009 

ABBOTT
ULTANE (LIQUID) SEVOFLURANE [GENERIC AN]
Drug Classes: ANESTHETICS, GENERAL
NDA Applicant: ABBOTT      NDA No.:
020478  Prod. No.: 001 RX (100%)
PatentsExpirationPatented Use
Pat. No. 5990176 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
Claim Types: Formulation; Method of improving a formulation
JUL 27,2017 *PED 
Pat. No. 6074668 Container for an inhalation anesthetic
Claim Types: Drug in a container
JUL 09,2018 *PED 
Pat. No. 6288127 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
Claim Types: Formulation; Method of improving a formulation
JUL 27,2017 *PED 
Pat. No. 6444859 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
Claim Types: Method of improving a formulation; Product-by-process
JUL 27,2017 *PED 

ABBOTT
ULTIVA (INJECTABLE) REMIFENTANIL HYDROCHLORIDE
NDA Applicant: ABBOTT      NDA No.:
020630  Prod. No.: 001 RX (EQ 1MG BASE/VIAL); 002 RX (EQ 2MG BASE/VIAL); 003 RX (EQ 5MG BASE/VIAL)
PatentsExpirationPatented Use
Pat. No. 5019583 [Extended 512 days (1.4 years)]
N-phenyl-N-(4-piperidinyl)amides useful as analgesics
Claim Types: Compound; Composition; Method of use
AUG 15,2009 *PED 
Pat. No. 5466700 Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
Claim Types: Method of use
MAR 01,2014 *PEDU-156: Method of providing anesthesia

ABBOTT
VICOPROFEN (TABLET) HYDROCODONE BITARTRATE; IBUPROFEN [GENERIC AB]
Drug Classes: ANALGESICS-NARCOTIC; NSAID; ANTITUSSIVES/EXPECTORANTS/MUCOLYTICS
NDA Applicant: ABBOTT      NDA No.:
020716  Prod. No.: 001 RX (7.5MG;200MG)
PatentsExpirationPatented Use
Pat. No. 6348216 Ibuprofen and narcotic analgesic compositions
Claim Types: Formulation
JUN 10,2017 
Pat. No. 6599531 Method of making ibuprofen and narcotic analgesic compositions
Claim Types: Product-by-process
JUN 10,2017 

ABBOTT
ZEMPLAR (INJECTABLE) PARICALCITOL
Drug Classes: VITAMINS/MINERALS
NDA Applicant: ABBOTT      NDA No.:
020819  Prod. No.: 001 RX (0.005MG/ML); 002 RX (0.002MG/ML)
PatentsExpirationPatented Use
Pat. No. 5246925 [Extended 574 days (1.6 years)]
19-nor-vitamin D compounds for use in treating hyperparathyroidism
Claim Types: Method of use
OCT 17,2012 *PEDU-314: Method for treating hyperparathyroidism which comprises suppressing parathyroid activity
Pat. No. 5587497 19-nor-vitamin D compounds
Claim Types: Compound
JUN 24,2014 *PED 
Pat. No. 6136799 Cosolvent formulations
Claim Types: Formulation; Process
OCT 08,2019 *PED 
Pat. No. 6361758 DP* Cosolvent formulations
Claim Types: Formulation
OCT 08,2018 *PED 
ExclusivityExpirationExclusivity Description
Exclusivity Code: M - MiscellaneousOct 01,2007 PEDM-31: Information for use in pediatric patients with chronic kidney disease Stage 5 (end-stage renal disease)

ABBOTT
ZEMPLAR (CAPSULE) PARICALCITOL
NDA Applicant: ABBOTT      NDA No.:
021606  Prod. No.: 001 RX (1UGM); 002 RX (2UGM); 003 RX (4UGM)
ExclusivityExpirationExclusivity Description
Exclusivity Code: NDF - New dosage formMAY 26,2008 

ACCESS PHARMS
AMLEXANOX (PATCH) AMLEXANOX
NDA Applicant: ACCESS PHARMS      NDA No.:
021727  Prod. No.: 001 RX (2MG)
ExclusivityExpirationExclusivity Description
Exclusivity Code: NDF - New dosage formSEP 29,2007 

ACCESS PHARMS
APHTHASOL (PASTE) AMLEXANOX
Drug Classes: DENTAL PREPARATIONS
NDA Applicant: ACCESS PHARMS      NDA No.:
020511  Prod. No.: 001 RX (5%)
PatentsExpirationPatented Use
Pat. No. 5362737 Methods of treating aphthous ulcers and other mucocutaneous disorders with amlexanox
Claim Types: Method of use
NOV 08,2011U-243: Topical administration

ACORDA
ZANAFLEX (CAPSULE) TIZANIDINE HYDROCHLORIDE
NDA Applicant: ACORDA      NDA No.:
021447  Prod. No.: 001 RX (EQ 2MG BASE); 002 RX (EQ 4MG BASE); 003 RX (EQ 6MG BASE)
PatentsExpirationPatented Use
Pat. No. 6455557 Method of reducing somnolence in patients treated with tizanidine
Claim Types: Method of improving a treatment
NOV 28,2021 

ACTELION
TRACLEER (TABLET) BOSENTAN
Drug Classes: ANTIHYPERTENSIVES
NDA Applicant: ACTELION      NDA No.:
021290  Prod. No.: 001 RX (62.5MG); 002 RX (125MG)
PatentsExpirationPatented Use
Pat. No. 5292740 Sulfonamides
Claim Types: Compound; Composition; Method of use
NOV 20,2015 
ExclusivityExpirationExclusivity Description
Exclusivity Code: NCE - New chemical entityNOV 20,2006 
Exclusivity Code ODE: Orphan DrugNOV 20,2008Treatment of pulmonary arterial hypertension.

ACTELION PHARMS
ZAVESCA (CAPSULE) MIGLUSTAT
NDA Applicant: ACTELION PHARMS      NDA No.:
021348  Prod. No.: 001 RX (100MG)
PatentsExpirationPatented Use
Pat. No. 5472969 Method of inhibiting glycolipid synthesis
Claim Types: Method of use
MAY 13,2013 
Pat. No. 5525616 Method of inhibiting glycolipid synthesis
Claim Types: Method of use
JUN 11,2013 
ExclusivityExpirationExclusivity Description
Exclusivity Code: NCE - New chemical entityJUL 31,2008 
Exclusivity Code ODE: Orphan DrugJUL 31,2010Use of Zavesca (miglustat) for the treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access)(Summarized from Approval Letter).

ADAMS LABS INC
MUCINEX (TABLET, EXTENDED RELEASE) GUAIFENESIN
NDA Applicant: ADAMS LABS INC      NDA No.:
021282  Prod. No.: 001 OTC (600MG); 002 OTC (1.2GM)
PatentsExpirationPatented Use
Pat. No. 6372252 Guaifenesin sustained release formulation and tablets
Claim Types: Formulation
APR 28,2020U-489: Expectorant

ADAMS LABS INC
MUCINEX D (TABLET, EXTENDED RELEASE) GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE
NDA Applicant: ADAMS LABS INC      NDA No.:
021585  Prod. No.: 001 OTC (600MG;60MG); 002 OTC (1.2GM;120MG)
PatentsExpirationPatented Use
Pat. No. 6372252 DP* Guaifenesin sustained release formulation and tablets
Claim Types: Formulation
APR 28,2020 

ADAMS LABS INC
MUCINEX DM (TABLET, EXTENDED RELEASE) DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN
NDA Applicant: ADAMS LABS INC      NDA No.:
021620  Prod. No.: 001 OTC (60MG;1.2GM); 002 OTC (30MG;600MG)
PatentsExpirationPatented Use
Pat. No.